Clinical management of cutaneous toxicity of anti-EGFR agents

Area of Science:

• Dermatology
• Oncology
• Molecular Biology

Background:

• Cutaneous toxicity is a common side effect of epidermal growth factor receptor (EGFR) inhibitors.
• EGFR plays a crucial role in skin physiology, leading to frequent dermatological adverse reactions, primarily folliculocentric.
• The precise mechanisms underlying these skin reactions are not fully understood, and their management remains a subject of debate.

Purpose of the Study:

• To review keratinocyte differentiation, activation, and gene expression pathways to enhance understanding of EGFR inhibitor-induced skin reactions.
• To present a clinical approach for managing skin reactions caused by cetuximab in patients with metastatic colorectal carcinoma.
• To explore the use of non-drug agents for treating drug-induced skin reactions.

Main Methods:

• Literature review of keratinocyte biology and gene expression pathways.
• Clinical case series involving patients treated with cetuximab for metastatic colorectal carcinoma.
• Evaluation of non-drug agents for managing skin toxicity.

Main Results:

• Understanding keratinocyte biology is key to managing EGFR inhibitor-induced skin reactions.
• Clinical management focused on controlling symptoms to prevent delays in cancer therapy.
• Non-drug agents were utilized in the treatment approach.

Conclusions:

• Improved understanding of skin biology aids in managing EGFR inhibitor-induced toxicity.
• Effective management of skin reactions is crucial for maintaining cancer treatment continuity.
• Non-drug interventions offer a viable strategy for managing dermatological side effects.